drugset
drugset / Trial / NCT05525520

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

NCT05525520 ↗

Phase 2 Completed 62 enrolled Escient Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)

Timeline

Start
2022-10-06
Primary completion
2024-07-17
Completion
2024-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject EP547 Unknown 100 mg —

Indications

No indication recorded.